JP2023537410A5 - - Google Patents
Info
- Publication number
- JP2023537410A5 JP2023537410A5 JP2023509739A JP2023509739A JP2023537410A5 JP 2023537410 A5 JP2023537410 A5 JP 2023537410A5 JP 2023509739 A JP2023509739 A JP 2023509739A JP 2023509739 A JP2023509739 A JP 2023509739A JP 2023537410 A5 JP2023537410 A5 JP 2023537410A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- hydrogen
- heterocycloalkyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064640P | 2020-08-12 | 2020-08-12 | |
| US63/064,640 | 2020-08-12 | ||
| PCT/US2021/045474 WO2022035923A1 (en) | 2020-08-12 | 2021-08-11 | Oxopyrrolidine urea fpr2 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537410A JP2023537410A (ja) | 2023-08-31 |
| JP2023537410A5 true JP2023537410A5 (https=) | 2024-08-19 |
| JP7802765B2 JP7802765B2 (ja) | 2026-01-20 |
Family
ID=77595649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509739A Active JP7802765B2 (ja) | 2020-08-12 | 2021-08-11 | オキソピロリジン尿素ｆｐｒ２アゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12565483B2 (https=) |
| EP (1) | EP4196471A1 (https=) |
| JP (1) | JP7802765B2 (https=) |
| KR (1) | KR20230051525A (https=) |
| CN (1) | CN116057055B (https=) |
| WO (1) | WO2022035923A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024220487A1 (en) * | 2023-04-18 | 2024-10-24 | Bristol-Myers Squibb Company | Carbocyclic phenylpyrrolidinone urea fpr2 agonists |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2752733T3 (es) | 2013-11-28 | 2020-04-06 | Kyorin Seiyaku Kk | Derivados de urea deuterados o marcados isotópicamente o sales farmacológicamente aceptables de los mismos útiles como agonistas de FPRL-1 |
| JP6746613B2 (ja) | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| JP6746614B2 (ja) | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| CN108348479A (zh) | 2015-11-24 | 2018-07-31 | 百时美施贵宝公司 | 靶向甲酰肽受体2/脂氧素a4受体(fpr2/alx)以用于治疗心脏疾病 |
| EP3414227B1 (en) | 2015-12-10 | 2021-11-24 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| JP2020015664A (ja) | 2016-11-21 | 2020-01-30 | 宇部興産株式会社 | 含窒素多環式ヘテロ環誘導体 |
| JP2020520948A (ja) | 2017-05-22 | 2020-07-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用 |
| WO2018227067A1 (en) * | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102623473B1 (ko) | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| CN110997653B (zh) * | 2017-06-09 | 2023-06-06 | 百时美施贵宝公司 | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 |
| US11008301B2 (en) | 2017-06-09 | 2021-05-18 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US10676431B2 (en) | 2018-03-05 | 2020-06-09 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| WO2020257161A1 (en) | 2019-06-18 | 2020-12-24 | Bristol-Myers Squibb Company | Biaryl dialkyl phosphine oxide fpr2 agonists |
| IL299680A (en) | 2020-07-09 | 2023-03-01 | Bristol Myers Squibb Co | Pyrazolone formyl peptide 2 receptor agonists |
| JP7771157B2 (ja) | 2020-07-09 | 2025-11-17 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン ｆｐｒ２アゴニスト |
| KR20230084530A (ko) | 2020-10-09 | 2023-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 아미노이미다졸 fpr2 효능제 |
-
2021
- 2021-08-11 JP JP2023509739A patent/JP7802765B2/ja active Active
- 2021-08-11 KR KR1020237008160A patent/KR20230051525A/ko active Pending
- 2021-08-11 CN CN202180056346.1A patent/CN116057055B/zh active Active
- 2021-08-11 WO PCT/US2021/045474 patent/WO2022035923A1/en not_active Ceased
- 2021-08-11 EP EP21763467.4A patent/EP4196471A1/en active Pending
- 2021-08-11 US US18/040,831 patent/US12565483B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050527A5 (https=) | ||
| RU2007124681A (ru) | Производные тетрагидропирана в качестве противодиабетических средств | |
| US5681824A (en) | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | |
| FI89356B (fi) | Foerfarande foer framstaellnig av blodsockerhalten saenkande samt atherosklerosis hindrande tiazolidindioner | |
| JPH0550516B2 (https=) | ||
| JP2024540164A5 (https=) | ||
| JP2019531320A5 (https=) | ||
| US20090131677A1 (en) | Substituted beta-phenyl-alpha-hydroxy-propanoic acid, synthesis method and use thereof | |
| JP2021514001A5 (https=) | ||
| JP2024540163A5 (https=) | ||
| JP2023537410A5 (https=) | ||
| JP3179599B2 (ja) | 縮合ベンゼンオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤 | |
| JP2021528451A5 (https=) | ||
| DE69434720T2 (de) | Verwendung von 2,6-Dialkyl-4-Silyl-Phenol Derivaten zur Behandlung von Xanthom | |
| JP2024543013A5 (https=) | ||
| JP2023533037A5 (https=) | ||
| JP2691679B2 (ja) | オキシム誘導体およびそれを含有する医薬品 | |
| JPS60208975A (ja) | 血小板活性化因子拮抗剤である新規２，５−ジアリ−ルテトラヒドロチオフエン類及びその類縁体 | |
| JP2021520394A5 (https=) | ||
| JPH08505362A (ja) | Ｐａｆレセプター拮抗剤及び５−リポキシゲナーゼ阻害剤としての、２，４−ジアリール−１，３−ジチオラン、２，４−ジアリール−１，３−ジオキソラン、２，４−ジアリール−１，３−オキサチオラン、及び２，５−ジアリール−１，３−オキサチオラン | |
| JP2022537350A5 (https=) | ||
| JPH01501551A (ja) | 新規な医薬用途 | |
| PT650485E (pt) | 2,5-diaril-tetra-hidro-tiofenos -furanos e analogos para o tratamento de desordens inflamatorias e imunitarias | |
| JP4443036B2 (ja) | ピラジン誘導体、それらの製造及びそれらを含有する薬剤 | |
| JP2826826B2 (ja) | アルキレンジアミン誘導体 |